Healthcare Marketing Impact Awards
Gold award for Digital campaign
Supplier/Vendor/Pharma, Minneapolis , MN
Qudexy XR launch
Upsher-Smith Laboratories released Qudexy XR extended-release capsules in June 2014 for use as an anti-seizure medication. Since that time, the medication failed to gain much traction in the market. In 2017, the Food and Drug Administration approved the drug for use to control migraines. Upsher-Smith shifted its marketing focus to migraines. Instead of outspending its competitors, Upsher-Smith took a more targeted approach and honed its message. It ran ads that reached its audience based on prescribing patterns, among other things. Between August 2017 and February 2018, the campaign resulted in more than 13 million ad impressions and 30,000 clicks.